PMC3290033_01
Normal magnetic resonance imaging (a, b) and diffusion-weighted magnetic resonance imaging (c) of the brain during an episode of irinotecan-induced dysarthria.
cro-0005-0047-g01.jpg
PMC3290033_01_cro-0005-0047-g01.jpg
F1
MR imaging of the brain, including diffusion weighted imaging, did not show any structural or perfusion abnormalities (fig. 1).
Abdominal CT scans showing liver metastases (arrows) before irinotecan (a), after 6 cycles of irinotecan (b), and after 9 cycles of irinotecan (c).
cro-0005-0047-g02.jpg
PMC3290033_01_cro-0005-0047-g02.jpg
F2
After an initial radiological response, treatment with irinotecan was stopped after 9 cycles because of progressive disease (fig. 2).